Back to today’s briefing

Story perspectives

Obicetrapib: Promising Breakthrough in Cholesterol Management

5/10/2025

41 7

Summary

Story summary

Obicetrapib, a groundbreaking CETP inhibitor, shows remarkable promise in reducing LDL and Lp(a) levels in patients battling heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. Recent trials, BROADWAY and TANDEM, confirm its safety and effectiveness, paving the way for improved cholesterol management and better patient outcomes. Hope is on the horizon for those in need!

1 of 1

Story summary

Obicetrapib, a groundbreaking CETP inhibitor, shows remarkable promise in reducing LDL and Lp(a) levels in patients battling heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. Recent trials, BROADWAY and TANDEM, confirm its safety and effectiveness, paving the way for improved cholesterol management and better patient outcomes. Hope is on the horizon for those in need!